Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer

This study has been terminated.
Sponsor:
Information provided by:
Chiron Corporation
ClinicalTrials.gov Identifier:
NCT00051688
First received: January 15, 2003
Last updated: July 10, 2006
Last verified: July 2006
  Purpose

The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.


Condition Intervention Phase
Colorectal Neoplasms
Drug: tezacitabine
Drug: oxaliplatin
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Chiron Corporation:

Study Start Date: June 2003
Estimated Study Completion Date: August 2004
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • Patients with metastatic colorectal adenocarcinoma who have failed one prior course of chemotherapy.
  • Patients must have at least one measurable tumor.
  • Patients may not have received prior treatment with oxaliplatin.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00051688

Locations
United States, Arizona
ACRC/Arizona Clinical Research Center
Tucson, Arizona, United States, 85712
United States, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Comprehensive Cancer Centers of the Desert
Palm Springs, California, United States, 92262
Cancer Institute Medical Group
Santa Monica, California, United States, 90404
United States, District of Columbia
Georgetown University Medical Center, Lombardi Cancer Center
Washington, District of Columbia, United States, 20007
United States, Florida
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States, 33612-9497
United States, Illinois
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States, 60611
United States, Missouri
Kansas City Oncology and Hematology Group
Kansas City, Missouri, United States, 64111
Sponsors and Collaborators
Chiron Corporation
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00051688     History of Changes
Other Study ID Numbers: TEZ101
Study First Received: January 15, 2003
Last Updated: July 10, 2006
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases
Oxaliplatin
Tezacitabine
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Radiation-Sensitizing Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014